A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
This article was originally published on MedicalXpress.com

